Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Urology. 2014 May 10;84(1):127–131. doi: 10.1016/j.urology.2014.03.015

Table 2.

AR CAG repeat length and risk of prostate cancer in PCPT controls and patients with low- and high-grade prostate cancer by TMPRSS2:ETS fusion status

No. Controls All prostate cancer with TMPRSS2:ETS status TMPRSS2:ETS negative TMPRSS2:ETS positive
No. Pts OR (95% CI) p-value No. Pts OR (95% CI) p-value No. Pts OR (95% CI) p-value
All prostate cancer
CAG categories 0.99 0.48 0.46
 Less than 19 (ref) 159 18 ref 10 ref 8 ref
 19–25 1032 160 1.37 (0.82–2.92) 75 1.16 (0.59–2.82) 85 1.64 (0.78–3.44)
 26+ 153 17 0.98 (0.49–1.98) 13 1.35 (0.58–3.17) 4 0.52 (0.15–1.76)
Per 1 CAG repeat increase 1344 195 1.00 (0.96–1.05) 0.91 98 1.04 (0.97–1.11) 0.29 97 0.97 (0.91–1.04) 0.37
Gleason 2–6
CAG categories 0.82 0.55 0.41
 Less than 19 (ref) 159 12 ref 6 ref 6 ref
 19–25 1032 121 1.55 (0.84–2.88) 48 1.23 (0.52–2.93) 73 1.88 (0.80–4.38)
 26+ 153 10 0.87 (0.36–2.06) 8 1.39 (0.47–4.09) 2 0.35 (0.07–1.74)
Per 1 CAG repeat increase 1344 143 1.00 (0.94–1.05) 0.91 62 1.04 (0.95–1.12) 0.41 81 0.97 (0.90–1.04) 0.38
Gleason 7–10
CAG categories 0.73 0.69 0.97
 Less than 19 (ref) 159 6 ref 4 ref 2 ref
 19–25 1032 38 0.98 (0.41–2.35) 26 1.00 (0.35–2.91) 12 0.92 (0.21–4.17)
 26+ 153 7 1.21 (0.40–3.69) 5 1.30 (0.34–4.93) 2 1.04 (0.15–7.47)
Per 1 CAG repeat increase 1344 51 1.01 (0.93–1.11) 0.76 35 1.03 (0.93–1.14) 0.59 16 0.98 (0.84–1.15) 0.81